⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer

Official Title: MoTriColor: Phase I/II Study With Galunisertib (LY2157299) Combined With Capecitabine in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and an Activated TGF-beta Signature

Study ID: NCT03470350

Interventions

Galunisertib

Study Description

Brief Summary: Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC. Part II is designed to obtain proof of principle of the galunisertib plus capecitabine combination in patients with chemo-resistant CRC. The combination of galunisertib plus capecitabine will be given as second line therapy in the phase II part of this study. Patients with chemotherapy resistant activated TGF-β signature-like tumors will have received a fluoropyrimidine (5FU or capecitabine) in the first line of chemotherapy, usually combined with oxaliplatin and, depending upon local hospital preferences or national guidelines, also bevacizumab, or cetuximab/panitumumab if the tumor is KRAS wild type. Addition of galunisertib to capecitabine should thus result in reversal of unresponsiveness, which is the first step in exploring this concept in the clinic. Capecitabine can be used as single agent in advanced CRC and is thus attractive for this study concept. If proof of principle is achieved also other tumor types can be explored with this genetic makeup, such as non-small cell lung cancer (NSCLC) in second line of treatment after platinum doublet therapy in first line, usually cisplatin/carboplatin-pemetrexed in non-squamous and cisplatin/carboplatin-gemcitabine or cisplatin/carboplatin-paclitaxel in squamous type NSCLC.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Noord-Holland, Netherlands

Contact Details

Name: J Tabernero, Prof

Affiliation: VHIO

Role: PRINCIPAL_INVESTIGATOR

Name: R Salazar, MD, PhD

Affiliation: ICO

Role: PRINCIPAL_INVESTIGATOR

Name: R Bernards, Prof

Affiliation: Agendia

Role: PRINCIPAL_INVESTIGATOR

Name: S Siena, Prof

Affiliation: ONCG

Role: PRINCIPAL_INVESTIGATOR

Name: A Cervantes, Prof

Affiliation: INCLIVA

Role: PRINCIPAL_INVESTIGATOR

Name: F Ciardiello, Prof

Affiliation: Unina2

Role: PRINCIPAL_INVESTIGATOR

Name: A Bardelli, Prof

Affiliation: UNITO

Role: PRINCIPAL_INVESTIGATOR

Name: S Tejpar, Prof

Affiliation: UZ Leuven

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: